<div class="tables frame-topbot rowsep-0 colsep-0" id="tbl3">
<div class="captions"><span id="cecap70"><p id="spara130"><span class="label">Table 3</span>. Prespecified adverse events of special interest</p></span></div>
<div class="groups"><table>
<thead><tr class="valign-top rowsep-1">
<th scope="col"></th>
<th scope="col" class="align-left"><strong>Albiglutide (n=4717)</strong></th>
<th scope="col" class="align-left"><strong>Placebo (n=4715)</strong></th>
<th scope="col" class="align-left"><strong>Relative risk (95% CI)</strong></th>
</tr></thead>
<tbody>
<tr class="valign-top">
<td class="align-left">Severe hypoglycaemia</td>
<td class="align-left">31 (1%)</td>
<td class="align-left">55 (1%)</td>
<td class="align-left">0·56 (0·36–0·87)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Pancreatitis<a name="btbl3fn1" href="#tbl3fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">10 (&lt;1%)</td>
<td class="align-left">7 (&lt;1%)</td>
<td class="align-left">1·43 (0·54–3·75)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Injection site reactions</td>
<td class="align-left">86 (2%)</td>
<td class="align-left">29 (1%)</td>
<td class="align-left">2·96 (1·95–4·51)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Thyroid cancer</td>
<td class="align-left">0 (0)</td>
<td class="align-left">0 (0)</td>
<td class="align-left">..</td>
</tr>
<tr class="valign-top">
<td class="align-left">Haematological neoplasia</td>
<td class="align-left">9 (&lt;1%)</td>
<td class="align-left">5 (&lt;1%)</td>
<td class="align-left">1·80 (0·60–5·36)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Pancreatic cancer</td>
<td class="align-left">6 (&lt;1%)</td>
<td class="align-left">5 (&lt;1%)</td>
<td class="align-left">1·20 (0·37–3·93)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Hypersensitivity syndrome or symptoms</td>
<td class="align-left">45 (1%)</td>
<td class="align-left">48 (1%)</td>
<td class="align-left">0·94 (0·63–1·40)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Hepatobiliary disorders</td>
<td class="align-left">51 (1%)</td>
<td class="align-left">41 (1%)</td>
<td class="align-left">1·24 (0·83–1·87)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Alanine aminotransferase of at least 3 times the ULN<a name="btbl3fn2" href="#tbl3fn2" class="workspace-trigger"><sup>†</sup></a>
</td>
<td class="align-left">17 (&lt;1%)</td>
<td class="align-left">30 (1%)</td>
<td class="align-left">0·57 (0·31–1·03)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Alanine aminotransferase of at least 5 times the ULN<a name="btbl3fn2" href="#tbl3fn2" class="workspace-trigger"><sup>†</sup></a>
</td>
<td class="align-left">6 (&lt;1%)</td>
<td class="align-left">17 (&lt;1%)</td>
<td class="align-left">0·35 (0·14–0·89)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Bilirubin of at least twice the ULN<a name="btbl3fn2" href="#tbl3fn2" class="workspace-trigger"><sup>†</sup></a>
</td>
<td class="align-left">12 (&lt;1%)</td>
<td class="align-left">7 (&lt;1%)</td>
<td class="align-left">1·71 (0·68–4·35)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Serious gastrointestinal events</td>
<td class="align-left">92 (2%)</td>
<td class="align-left">87 (2%)</td>
<td class="align-left">1·06 (0·79–1·41)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Appendicitis</td>
<td class="align-left">3 (&lt;1%)</td>
<td class="align-left">8 (&lt;1%)</td>
<td class="align-left">0·37 (0·10–1·41)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Atrial fibrillation or flutter</td>
<td class="align-left">108 (2%)</td>
<td class="align-left">131 (3%)</td>
<td class="align-left">0·82 (0·64–1·06)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Pneumonia</td>
<td class="align-left">131 (3%)</td>
<td class="align-left">138 (3%)</td>
<td class="align-left">0·95 (0·75–1·20)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Renal impairment<a name="btbl3fn3" href="#tbl3fn3" class="workspace-trigger"><sup>‡</sup></a>
</td>
<td class="align-left">279 (6%)</td>
<td class="align-left">319 (7%)</td>
<td class="align-left">0·87 (0·75–1·02)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Diabetic retinopathy</td>
<td class="align-left">78 (2%)</td>
<td class="align-left">89 (2%)</td>
<td class="align-left">0·88 (0·65–1·18)</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="spara140">Data are number of patients (%), in those who took at least one dose. Details of specified events are reported in the <a name="bsec1" href="#sec1" class="workspace-trigger">appendix</a>. ULN=upper limit of normal.</p>
<dl class="footnotes">
<dt id="tbl3fn1">*</dt>
<dd><p id="cenpara50">Events prospectively adjudicated to be definite or possible pancreatitis by a treatment-blind adjudication committee.</p></dd>
<dt id="tbl3fn2">†</dt>
<dd><p id="cenpara60">Hepatic
 enzyme elevation was prespecified as an adverse event of special 
interest. There were four patients who had an alanine aminotransferase 
concentration of at least 3 times the ULN and a bilirubin concentration 
of at least twice the ULN: one patient in the albiglutide group, three 
patients in the placebo group.</p></dd>
<dt id="tbl3fn3">‡</dt>
<dd><p id="cenpara70">Acute kidney injury was reported by investigators in 70 patients in the albiglutide group and 80 patients in the placebo group.</p></dd>
</dl>
</div>